COLL - Collegium Pharmaceutical Inc
(NaN%)
Hold
Moderate Growth and Improving
47%
based on last 5 year data.
Income Statement is MODERATE
Revenue Growth is 5.79%
Operating Income Growth is 71.75%
Net Income Growth is 488.35%
Earnings Per Share (EPS) Growth is 434.69%
Net Margin is 31.77%
Balance Sheet is WEAK
Current Asset to Current Liability Ratio is 1.35
Debt Ratio is 0.66
Current Debt to Net Income Ratio is 5.98
Total Debt to Total Assets Ratio is 0.06
Cash Flow is MODERATE
Cash from Operations Growth is 3.35%
Capital Expenditure is Low
Net Increase in Cash is Positive
Long Term Score Trend is POSITIVE
Investment Risk is Low
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Collegium Pharmaceutical Inc (COLL) - www.collegiumpharma.com
Collegium Pharmaceutical Inc. is a specialty pharmaceutical company committed to being the leader in responsible pain management. Collegium's headquarters are located in Stoughton, Massachusetts.Exchange - NASDAQ/NGS (GLOBAL SELECT MARKET)
Industry - Pharmaceutical Preparation Manufacturing
Sector - Manufacturing
CEO -
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.
Know the Stock © 2021 and future.